Are Wall Street Analysts Bullish on Schlumberger Stock?
The stock has significantly underperformed the broader market over the past year. SLB has plunged 10.9% on a YTD basis and 28.2% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 8.2% surge in 2025 and 17% gains over the past year.
More News from Barchart
Morgan Stanley Says Nvidia Has 'Exceptional' Strength. Should You Buy NVDA Stock Here?
This Dividend Stock Yields 4.5% But Is Down 21% in 2025: Time to Buy?
Dear MicroStrategy Stock Fans, Mark Your Calendars for July 31
Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today!
Zooming in further, Schlumberger has also lagged behind the Energy Select Sector SPDR Fund's (XLE) 2.4% uptick in 2025 and 5.5% drop over the past 52 weeks.
Schlumberger's stock prices dropped 3.9% following the release of its mixed Q2 results on Jul. 18. While the company's financials observed a slight improvement from Q1, they remained underwhelming on a year-on-year basis. Its topline for the quarter dropped 6.5% year-over-year to $8.5 billion. Meanwhile, its adjusted EPS dropped 12.9% year-over-year to $0.74, but exceeded the consensus estimates by 1.4%.
Nevertheless, its aggregated operating cash flows of Q1 and Q2 have inched up 2.2% year-over-year to $1.8 billion. Following the initial dip, SLB maintained a positive momentum for the next six trading sessions.
For the full fiscal 2025, ending in December, analysts expect SLB to deliver an adjusted EPS of $2.88, down 15.5% year-over-year. The company has a mixed earnings surprise history. While it missed the Street's bottom-line estimates once over the past four quarters, it has surpassed the projections on three other occasions.
The stock holds a consensus 'Strong Buy' rating overall. Of the 23 analysts covering the stock, opinions include 15 'Strong Buys,' four 'Moderate Buys,' and four 'Holds.'
This configuration is slightly less bullish than two months ago, when 16 analysts gave 'Strong Buy' recommendations.
On Jul. 21, Susquehanna analyst Bascome Majors reiterated a 'Positive' rating on SLB, but lowered the price target from $44 to $42.
SLB's mean price target of $46.56 represents a 36.3% premium to current price levels, while the Street-high target of $64.50 suggests an 88.8% upside potential.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 minutes ago
- Business Wire
Codasip looks to Silicon Creations' PLL to drive RSIC-V Automotive Safety-Critical Core
ATLANTA--(BUSINESS WIRE)-- Silicon Creations, a leading provider of high-performance analog and mixed-signal intellectual property (IP) today announced that its low-area integer PLL has been successfully integrated into Codasip's latest test chip, enabling the evaluation of Codasip's L31AS dual-core lock-step CPU and crypto accelerator IP. The collaboration marks a key milestone in the deployment of robust and efficient clocking solutions for automotive-grade RISC-V systems. Designed for automotive applications, Codasip's L31AS CPU is a safety-critical, high-performance RISC-V core. To meet the stringent clocking requirements of this environment, Codasip selected Silicon Creations' low-area integer PLL for its ultra-small footprint, proven silicon track record, ease of integration, and excellent low-jitter digital clock generation. The integration delivered the precise clocking performance needed while minimizing silicon area and system complexity. 'We are thrilled to support Codasip's innovative RISC-V processor development with our area-optimized digital clocking PLL,' said Randy Caplan, co-founder of Silicon Creations. 'This partnership highlights not only the flexibility of our PLL technology but also how optimized clocking solutions can help accelerate the delivery of automotive-grade, high-performance computing platforms.' Paul Elliott, Senior Security and Safety Architect at Codasip, commented, 'The successful integration of Silicon Creations' PLL into our L31AS dual-core test chip is a significant step for Codasip. As we advance our automotive and embedded system solutions, the reliability and performance of this PLL will play a critical role in supporting our next-generation designs.' With several upcoming projects requiring precise and efficient PLL technology, Codasip's successful test chip evaluation reinforces its commitment to driving innovation in RISC-V-based technologies for the automotive and embedded markets. The collaboration with Silicon Creations demonstrates the importance of strategic IP partnerships in accelerating time-to-market while meeting stringent industry requirements. About Codasip Codasip is a leading provider of customizable processor cores and associated toolchains, specializing in RISC-V-based architectures. The company offers high-performance, energy-efficient solutions for a wide range of applications, including automotive, embedded systems, and IoT. Codasip's flexible and scalable designs meet the growing demands of the semiconductor industry with future-proof solutions. About Silicon Creations Silicon Creations provides world-class silicon intellectual property (IP) for precision and general-purpose timing PLLs, SerDes and high-speed differential I/Os. Silicon Creations' IP is in production from 3 to 180 nanometer process technologies, with 2nm GDS available for deployment. With a complete commitment to customer success, its IP has an excellent record of first silicon to mass production in customer designs. Silicon Creations, founded in 2006, is self-funded and growing. The company has development centers in Atlanta, USA, and Krakow, Poland, and worldwide sales representation. For more information, visit All reference to Silicon Creations trademarks are the property of Silicon Creations, Inc. All other trademarks mentioned herein are the property of their respective owners.
CNBC
6 minutes ago
- CNBC
What's driving the action in Amazon's stock, plus our hopes for Disney earnings
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Tuesday's key moments. 1. U.S. stocks were down Tuesday as Wall Street digested lackluster economic data and new quarterly earnings reports. The ISM services index came in a bit weaker than expected, weighing on investor sentiment. Meanwhile, Palantir's blowout earnings release moved the tech-heavy Nasdaq Composite higher briefly in early trading, but has since lost steam. The biggest losses were seen in the Dow Jones Industrial Average and S & P 500 , which slipped 0.4% and 0.3%, respectively. 2. Club holding Walt Disney reports quarterly earnings on Wednesday. We hope to see continued resilience in the company's theme parks, and will be looking out for profitability in its streaming division. Shares of the entertainment giant are down more than 1% Tuesday — a move that Jim Cramer celebrates ahead of the release. "I wanted it to come down," he said. "This is much better." That's because when a stock is up significantly into earnings, investors are more likely to treat the release as a "sell the news" event. 3. Amazon shares are up over 1% Tuesday following the Big Tech name's post-earnings decline. In fact, between last Friday and Monday's close, the stock dropped roughly 10%. Jim cited investor concerns over Amazon's dominance in its cloud computing business for the weakness as competitors like Alphabet- owned Google and OpenAI grabbed share. We're standing by the stock for now though. "I think it's not as clear cut as people think," Jim said. "I would point out that it has a huge business." The solution, Jim said, is for Amazon to spend more on Nvidia chips in order to improve its crucial cloud computing division. "Could it accelerate? Yes, [but] they have to get away from their own chips where they're viewed as not being as powerful." 4. Stocks covered in Tuesday's rapid fire at the end of the video were: Palantir, Caterpillar , Yum Brands , Pfizer and Marriott International. (Jim Cramer's Charitable Trust is long DIS, AMZN, NVDA. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Yahoo
8 minutes ago
- Yahoo
Pfizer posts strong earnings despite Trump's new 'up to 250%' tariff threat
Pharmaceutical giant Pfizer reported better-than-expected quarterly results on Tuesday and improved its predictions for full-year profits, beating Wall Street expectations. The New York-based company reported second-quarter sales of $14.7 billion (€12.74bn) and earnings per share of $0.51 (€0.44). As of around 16.00 CEST, Pfizer shares were up over 4% at $24.58. "Our business is performing well and I'm pleased with the progress we achieved in the second quarter," chairman and CEO Albert Bourla said in a statement. "We continue to be actively engaged with policymakers as we navigate a complicated and rapidly evolving geopolitical environment while also remaining focused on advancing our business," Bourla continued. This despite several policies announced by the current US administration that could hurt drugmakers. Related Irish exports hit record high with pharmaceuticals showing major boost EU Commission loses on all counts in Pfizergate legal case In May, US President Donald Trump signed an executive order whereby pharmaceutical companies would be compelled to lower prices based on a "Most Favored Nation" policy. The price-slashing scheme seeks to ban drug companies from selling products in the US at prices above those in other developed countries. In Europe, the comparison becomes complex, as a significant portion pharmaceutical costs are covered by national healthcare or insurance systems, lowering prices for consumers. Experts warned at the time that this could slash their US revenues and affect availability. Even so, the president doubled down on his plans, sending letters last week to 17 drugmakers, calling for concrete steps to cut prices by 29 September. That includes agreeing to provide their full portfolio of existing medicines at no higher than European prices to every single Medicaid patient. On Tuesday, in an interview with CNBC, he announced that tariffs for pharmaceuticals and semiconductors would be coming in "next week". 'We'll be putting an initially small tariff on pharmaceuticals, but in one year, one-and-a-half years, maximum, it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country," he told CNBC. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
